Skybiotech Healthcare Share Price
115.00-5.00 (-4.17%)
-32.51% past 1 Year
Corporate filings & documents
Announcements
Intimation of Notice of Annual General Meeting propose to be held on 30th September 2026
2 weeks agoIntimation of Notice of Annual General Meeting propose to be held on 30th September 2026
2 weeks agoSubmission of Annual Report for Financial Year 2025-2026
2 weeks agoSubmission of Annual Report for Financial Year 2025-2026
2 weeks agoUn-Audited Financial Results for the quarter ended on 30th June 2026
1 month agoUn-Audited Financial Results for the quarter ended on 30th June 2026
1 month agoOutcome of Board Meeting dated 14th August 2026 to considered and approved the Un-audited Financial Results of Company for the quarter ended on 30th June 2026
1 month agoOutcome of Board Meeting dated 14th August 2026 to considered and approved the Un-audited Financial Results of Company for the quarter ended on 30th June 2026
1 month agoSkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Un-Audited financial results and limited review report of the Company for the Quarter ended on June 30 2026.
1 month agoSkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Un-Audited financial results and limited review report of the Company for the Quarter ended on June 30 2026.
1 month agoCompliance Certificate under Regulation 74(5) of SEBI (DP) Regulation
2 months agoCompliance Certificate under Regulation 74(5) of SEBI (DP) Regulation
2 months agoIntimation of Trading Window Closure to consider and approve un-audited financial results for the quarter ended on 30th June 2026
2 months agoIntimation of Trading Window Closure to consider and approve un-audited financial results for the quarter ended on 30th June 2026
2 months agoSubmission of Financial Results for the Quarter and Year ended on 31st March 2026
3 months agoSubmission of Financial Results for the Quarter and Year ended on 31st March 2026
3 months agoSubmission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
3 months agoSubmission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
3 months agoSkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve Approval of Audited Results for the Quarter and Year ended on March 31 2026
3 months agoSkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve Approval of Audited Results for the Quarter and Year ended on March 31 2026
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Skybiotech Healthcare Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L17100MH1983PLC031114</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NISHI JAIN <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRAKASHCHANDRA RATHI <br/> Designation: CFO AND DIRECTOR <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Reg. 74(5) of SEBI (DP) Regulation 2018 received from RTA
5 months agoCertificate under Reg. 74(5) of SEBI (DP) Regulation 2018 received from RTA
5 months agoIntimation of Trading window closure to consider and approve Audited Financials for the Quarter and year ended on 31st March 2026
5 months agoIntimation of Trading window closure to consider and approve Audited Financials for the Quarter and year ended on 31st March 2026
5 months agoSubmission of Un-Audited Financial Results for the Quarter ended on 31st December 2025
7 months agoSubmission of Un-Audited Financial Results for the Quarter ended on 31st December 2025
7 months agoOutcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December 2025
7 months agoOutcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December 2025
7 months agoSkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Approval of Unaudited Financial Results for the Quarter ended on 31st December 2025
7 months agoCompliance certificate Under Reg. 74(5) of SEBI (DP) Regulation 2018 for the quarter ended on 31st December 2025
8 months agoIntimidation of initiation of Trading Window Closure for the Quarter ended on 31st December 2025
8 months agoRevised Un-audited Financial Results for the quarter ended on 30th September 2025
10 months agoUn-Audited Financial Results for quarter ended on 30th September 2025
10 months agoOutcome of Board Meeting held on 14th November 2025 to Considered and approved Un-audited Financials Results for the quarter ended on 30th September 2025
10 months agoKapil Cotex Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Consideration and approval of Unaudited Financial Results for the half year ended September 30 2025
10 months agoReceipt of Approval of Registrar of Company (ROC) for Change of Name from Kapil Cotex Limited to Skybiotech Healthcare Limited
10 months agoCompliance Certificate Under Regulation 74(5) of SEBI (DP) Regulation for the Quarter ended on 30th September 2025
11 months agoScrutinizer Report of AGM
11 months agoIntimation regarding Trading Window Closure for approval of unaudited financial results of Company for the Quarter and half year ended 30th September 2025
12 months agoProceeding of 42nd Annual General Meeting of Kapil Cotex Limited
12 months agoOutcome of 42nd Annual General Meeting of Kapil Cotex Limited
12 months agoAnnual reports
Concalls & investor presentations
No presentations found